Target intelligence / Profile preview

Beta-mammal toxin CeII-9 (CeII-9)

Target
CeII-9
Molecular classification
Scorpion venom toxin, Beta-mammal toxin, Sodium channel modulator
01

Overview

Centruroides elegans CeII9 (also known as Beta-mammal toxin CeII-9) is a potent neurotoxin isolated from the venom of the Mexican scorpion Centruroides elegans [1]. It belongs to the beta-class of scorpion toxins, which are characterized by their ability to modulate the gating mechanism of voltage-gated sodium channels (Nav) [2]. Specifically, CeII9 binds to neurotoxin receptor site 4 on the sodium channel, shifting the voltage-dependence of activation toward more hyperpolarized potentials and reducing the peak sodium current [1, 2]. This action causes the channels to open at more negative membrane potentials, leading to spontaneous and repetitive firing of action potentials in neurons and muscle fibers [3]. Clinically, this results in severe envenomation symptoms, including muscle spasms, respiratory distress, and cardiovascular instability [2]. While CeII9 is not a therapeutic target for treating human diseases, it is the primary target for neutralization by therapeutic antivenoms such as Alacramyn [2]. In pharmacological research, CeII9 is used as a high-affinity probe to investigate the structural biology of sodium channels and the molecular basis of channelopathies [1, 3].

Other names
Toxin CeII-9CeII9Centruroides elegans toxin 9
02

Mechanism of action

Neutralization of the toxin by specific antibody fragments, preventing its binding to voltage-gated sodium channels [2].

03

Biological functions

Voltage-gated sodium channel modulationNeurotoxicityInduction of neurotransmitter release
04

Disease associations

Scorpion envenomation
05

Safety considerations

Severe neurotoxicityRespiratory failureAutonomic stormCardiovascular collapse
06

Interacting drugs

Centruroides immune F(ab')2 (equine)

1 more in the full profile.

07

Biomarkers

Serum venom antigen levelsCreatine phosphokinase (CPK) elevationBlood glucose levels (hyperglycemia)

Beyond the preview

Go deeper on Beta-mammal toxin CeII-9 (CeII-9).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beta-mammal toxin CeII-9 (CeII-9).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call